Your browser is no longer supported. Please, upgrade your browser.
Settings
NBRV [NASD]
Nabriva Therapeutics plc
Index- P/E- EPS (ttm)-5.83 Insider Own1.00% Shs Outstand34.79M Perf Week-9.64%
Market Cap55.61M Forward P/E- EPS next Y-1.23 Insider Trans0.00% Shs Float24.75M Perf Month-26.83%
Income-69.50M PEG- EPS next Q-0.57 Inst Own13.50% Short Float10.18% Perf Quarter-50.82%
Sales5.00M P/S11.12 EPS this Y51.50% Inst Trans8.50% Short Ratio1.11 Perf Half Y-75.39%
Book/sh2.05 P/B0.73 EPS next Y33.20% ROA-125.60% Target Price- Perf Year-70.41%
Cash/sh1.12 P/C1.34 EPS next 5Y- ROE-207.80% 52W Range1.40 - 12.00 Perf YTD-38.02%
Dividend- P/FCF- EPS past 5Y53.00% ROI-169.20% 52W High-87.50% Beta1.81
Dividend %- Quick Ratio2.80 Sales past 5Y5.90% Gross Margin84.80% 52W Low7.14% ATR0.16
Employees72 Current Ratio3.10 Sales Q/Q733.30% Oper. Margin- RSI (14)36.65 Volatility10.75% 9.25%
OptionableYes Debt/Eq0.23 EPS Q/Q61.50% Profit Margin- Rel Volume0.55 Prev Close1.57
ShortableYes LT Debt/Eq0.17 EarningsMar 11 AMC Payout- Avg Volume2.27M Price1.50
Recom2.70 SMA20-12.43% SMA50-30.82% SMA200-65.90% Volume1,258,536 Change-4.46%
Mar-19-20Downgrade Wedbush Outperform → Neutral
May-02-19Upgrade Gabelli & Co Sell → Hold
May-02-19Reiterated H.C. Wainwright Buy $9 → $7
Sep-07-18Resumed Morgan Stanley Overweight
Mar-21-18Initiated BofA/Merrill Buy $10
Jan-17-18Initiated Morgan Stanley Overweight
Nov-01-17Reiterated H.C. Wainwright Buy $18 → $20
Aug-25-17Initiated SunTrust Buy $20
Feb-01-17Reiterated Wedbush Outperform $13
Oct-27-16Resumed Leerink Partners Outperform $14
Sep-08-16Initiated H.C. Wainwright Buy $16
Jan-27-16Initiated Gabelli & Co Buy $14
Nov-12-15Reiterated RBC Capital Mkts Outperform $21 → $22
Oct-13-15Initiated Wedbush Outperform
Oct-13-15Initiated RBC Capital Mkts Outperform $21
Oct-13-15Initiated Leerink Partners Outperform $19
Oct-12-15Initiated Needham Buy $15
Apr-15-21 12:12PM  
Apr-14-21 09:38AM  
06:49AM  
Apr-09-21 09:40AM  
Apr-06-21 09:05AM  
Apr-05-21 06:39AM  
Apr-02-21 04:01PM  
Apr-01-21 08:17AM  
08:00AM  
Mar-25-21 07:57AM  
Mar-18-21 08:57AM  
Mar-16-21 08:00AM  
Mar-11-21 04:07PM  
02:30PM  
Mar-09-21 07:27AM  
Mar-03-21 04:05PM  
Mar-01-21 08:00AM  
Feb-26-21 08:00AM  
Feb-17-21 10:04AM  
Feb-02-21 08:05AM  
Feb-01-21 04:30PM  
Jan-05-21 04:01PM  
Dec-10-20 11:18PM  
11:05PM  
04:01PM  
Dec-07-20 07:00AM  
Dec-02-20 08:00AM  
Nov-12-20 07:01AM  
Nov-05-20 04:01PM  
02:45PM  
Nov-03-20 06:06AM  
Nov-02-20 04:01PM  
Oct-13-20 07:00AM  
Sep-10-20 08:39AM  
Aug-31-20 07:00AM  
Aug-06-20 04:01PM  
Aug-03-20 07:00AM  
Jul-30-20 04:01PM  
Jul-29-20 10:21AM  
Jul-28-20 10:02AM  
Jul-23-20 07:00AM  
Jul-17-20 11:12AM  
07:41AM  
Jul-16-20 04:04PM  
12:00PM  
Jul-15-20 04:01PM  
Jun-23-20 09:12PM  
Jun-22-20 03:23PM  
Jun-19-20 08:52PM  
07:41AM  
Jun-10-20 08:39AM  
Jun-08-20 07:19AM  
Jun-01-20 04:00PM  
08:40AM  
May-29-20 07:31PM  
08:00AM  
May-27-20 04:01PM  
May-18-20 08:00AM  
May-11-20 04:01PM  
07:00AM  
May-08-20 07:00AM  
May-07-20 08:32AM  
May-05-20 07:00AM  
Apr-14-20 08:59AM  
Apr-09-20 07:00AM  
Apr-08-20 07:00AM  
Apr-02-20 10:08AM  
Mar-17-20 09:33AM  
Mar-12-20 04:01PM  
02:30PM  
Mar-10-20 04:01PM  
Mar-05-20 08:21AM  
Mar-03-20 09:38AM  
Mar-02-20 04:01PM  
Feb-05-20 04:01PM  
Jan-22-20 08:24AM  
Jan-09-20 08:39AM  
Jan-08-20 04:01PM  
Dec-20-19 03:06PM  
08:37AM  
06:44AM  
06:00AM  
Dec-19-19 09:38PM  
Dec-10-19 10:31AM  
Dec-02-19 04:01PM  
Nov-23-19 06:55PM  
Nov-21-19 04:01PM  
Nov-20-19 07:49PM  
Nov-18-19 07:00AM  
Nov-12-19 04:01PM  
Nov-01-19 04:01PM  
Oct-31-19 07:00AM  
Oct-15-19 07:00AM  
Oct-11-19 06:32PM  
Oct-01-19 04:01PM  
10:07AM  
Sep-27-19 12:15PM  
Sep-26-19 04:01PM  
Sep-18-19 07:00AM  
Sep-11-19 09:32AM  
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI). It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Broom Colin MDDirectorAug 20Sale0.6511,0647,165248,936Aug 21 07:02 PM